Symptomatic Treatment of Multiple Sclerosis

  title={Symptomatic Treatment of Multiple Sclerosis},
  author={Thomas Henze and Peter Rieckmann and Klaus Victor Toyka},
  journal={European Neurology},
  pages={78 - 105}
Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different… 
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice
The literature on the comorbidities and symptoms of MS are reviewed and the evidence for treatments that have been or may be used to alleviate them are summarized.
Exercise in multiple sclerosis -- an integral component of disease management
The current knowledge on the influence of physical activity and exercise on disease-related symptoms and physical restrictions in MS patients is summarized.
Recommendations for diagnosis and management of multiple sclerosis.
Guidelines for the management of MS should be focused on the diagnosis of MS; treatment of relapses; and long-term preventive treatment including clinical follow up, dose adjustment, drug switch, control of therapeutic efficacy, and disease progression.
Multiple Sclerosis: Therapeutic Strategies on the Horizon
The pathogenesis of MS, management of acute relapses, disease-modifying therapies in MS, new drugs and drugs currently in trial for MS and the symptomatic treatment of MS are discussed.
Yoga as a method of symptom management in multiple sclerosis
The objective of the present review is to examine the potential benefits of yoga for individuals with MS and address its use in managing symptoms including pain, mental health, fatigue, spasticity, balance, bladder control, and sexual function.
Symptom management in patients with multiple sclerosis
  • T. Ziemssen
  • Medicine
    Journal of the Neurological Sciences
  • 2011
An observational study
A correlation has been found between therapeutic adherence, adaptive coping strategies, and mental health when drug therapy is administered by injection, suggesting that for patients receiving injection treatment to have greater adherence to therapy, appropriate coping strategies and good mental health must be developed.
Therapeutic Advances in Neurological Disorders
Current evidence for the efficacy and safety of δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity is reviewed.
Symptomatic management in multiple sclerosis
  • Pushkar Shah
  • Medicine, Psychology
    Annals of Indian Academy of Neurology
  • 2015
For many patients such as those with primary progressive MS (PPMS) and those that inevitably become secondary progressive, symptom management is the only treatment available.


Symptomatic therapy of multiple sclerosis.
Recent developments in the management of primary symptoms of multiple sclerosis including visual loss, weakness, spasticity, urinary and sexual dysfunction, and fatigue are emphasized.
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].
This update of the consensus on escalating immunotherapy in multiple sclerosis includes for the first time also important aspects of diagnosis, documentation, and cost of disease. The application of
Escalating immunotherapy of multiple sclerosis
The MSTCG panel recommends that the new diagnostic criteria proposed by McDonald et al should be applied if immunoprophylactic treatment is being considered and the use of standardized clinical documentation is now generally proposed to facilitate the systematic evaluation of individual patients over time and to allow retrospective evaluations in different patient cohorts.
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
Clinical trials study patients for only short periods of time (2 or 3 years) and, therefore, use only short-term outcome measures to assess efficacy, and evaluation of the relative effectiveness of different therapies requires consideration of which outcome measure or measures are relevant to the goals of therapy.
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Only amantadine and pemoline appear to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term.
Modafinil in treatment of fatigue in multiple sclerosis
Treatment with modafinil significantly improves fatigue and sleepiness and is well tolerated by patients with MS, unlike the higher dose regimen required in narcolepsy.
Effects of neuropsychological treatment in patients with multiple sclerosis
It is worth while to offer specific neuropsychological treatment to MS patients with cognitive and behavioral dysfunction, and on the Beck Depression Inventory (BDI) the specific cognitive treatment group reported significantly less depression.
Experimental therapies for multiple sclerosis: current status.
The results of clinical trials of experimental therapeutic agents in multiple sclerosis are reviewed, the background and action of each treatment are described, and the clinical experience with each agent is reviewed.
Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)
This evidence-based review addresses some of the major management issues in patients with ALS, and highlights the many areas in which more research is needed, as well as developing practice parameters for physicians.
Amantadine treatment of fatigue associated with multiple sclerosis.
Although retrospective reports by patients with MS did not confirm the degree of improvement recorded on a daily basis, the study's results suggested that amantadine may offer modest benefits in alleviate the day-to-day subjective experience of fatigue.